Efficiency and safety of Pulmicort-turbuhaler treatment in patients with bronchial asthma exacerbations who did not use to receive any inhaled glucocorticosteroids

Abstract

Eighteen non-smoking patients (13 females and 5 males) with severe non-atopic bronchial asthma exacerbation, who had not been treated with any glucocorticosteroids before now, received Pulmicort-turbuhaler during 4 weeks in the dose 1000 meg daily. Besides of a dynamic evaluation of the clinical signs score and daily need for β₂-agonists, a bronchial response to p2-agonists in lung functional test was also checked before the treatment and after the 1-st, the 2-nd, the 4-th week of the treatment. Local and systemic adverse events were controlled by an inspection of an oral cavity, a dynamic investigation of 11 -oxycorticosteroids, insulin, glucose and electrolytes levels and blood biochemical parameters.
Four-week treatment course was effective in 89% of patients that was demonstrated by the clinical signs regression and improvement in lung function parameters up to the level appropriate to a mild bronchial obstruction.
The FEV₁ increase by more than 25% at the salbutamol test after the 1 -st, the 2-nd, the 4-th week of the treatment appears to be the evidence of a bronchial hyperreactivity. A local irritation of mucous membrane was found in 2 patients from 18. Any systemic effects were not revealed.
Thus, the obtained data confirm the fact of a high anti-inflammatory activity of Pulmicort-turbuhaler. The examination of its safety has not found any systemic adverse events. These results according to the high clinical efficiency and the comfortable application allow to recommend this drug as a drug of choice for patients with severe bronchial asthma exacerbations who did not use to be treated with any glucocorticosteroids. Эффективность и безопасность применения пульмикорта-турбухалера 1000 мкг/сутки у больных с обострением бронхиальной астмы, ранее не получавших ингаляционные глю ко кортикостероиды.